327 related articles for article (PubMed ID: 34279051)
1. Dietary fiber-derived short-chain fatty acids: A potential therapeutic target to alleviate obesity-related nonalcoholic fatty liver disease.
Zhang S; Zhao J; Xie F; He H; Johnston LJ; Dai X; Wu C; Ma X
Obes Rev; 2021 Nov; 22(11):e13316. PubMed ID: 34279051
[TBL] [Abstract][Full Text] [Related]
2. Short-chain fatty acids in nonalcoholic fatty liver disease: New prospects for short-chain fatty acids as therapeutic targets.
Li X; He M; Yi X; Lu X; Zhu M; Xue M; Tang Y; Zhu Y
Heliyon; 2024 Mar; 10(5):e26991. PubMed ID: 38486722
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in the therapeutic application of short-chain fatty acids (SCFAs): An updated review.
Rauf A; Khalil AA; Rahman UU; Khalid A; Naz S; Shariati MA; Rebezov M; Urtecho EZ; de Albuquerque RDDG; Anwar S; Alamri A; Saini RK; Rengasamy KRR
Crit Rev Food Sci Nutr; 2022; 62(22):6034-6054. PubMed ID: 33703960
[TBL] [Abstract][Full Text] [Related]
4. A bridge for short-chain fatty acids to affect inflammatory bowel disease, type 1 diabetes, and non-alcoholic fatty liver disease positively: by changing gut barrier.
Liu W; Luo X; Tang J; Mo Q; Zhong H; Zhang H; Feng F
Eur J Nutr; 2021 Aug; 60(5):2317-2330. PubMed ID: 33180143
[TBL] [Abstract][Full Text] [Related]
5. From gut microbiota dysfunction to obesity: could short-chain fatty acids stop this dangerous course?
Barrea L; Muscogiuri G; Annunziata G; Laudisio D; Pugliese G; Salzano C; Colao A; Savastano S
Hormones (Athens); 2019 Sep; 18(3):245-250. PubMed ID: 30840230
[TBL] [Abstract][Full Text] [Related]
6. Dietary Fiber in Bilberry Ameliorates Pre-Obesity Events in Rats by Regulating Lipid Depot, Cecal Short-Chain Fatty Acid Formation and Microbiota Composition.
Liu HY; Walden TB; Cai D; Ahl D; Bertilsson S; Phillipson M; Nyman M; Holm L
Nutrients; 2019 Jun; 11(6):. PubMed ID: 31208043
[TBL] [Abstract][Full Text] [Related]
7. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.
Porras D; Nistal E; Martínez-Flórez S; Pisonero-Vaquero S; Olcoz JL; Jover R; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S
Free Radic Biol Med; 2017 Jan; 102():188-202. PubMed ID: 27890642
[TBL] [Abstract][Full Text] [Related]
8. Short-chain fatty acids: microbial metabolites that alleviate stress-induced brain-gut axis alterations.
van de Wouw M; Boehme M; Lyte JM; Wiley N; Strain C; O'Sullivan O; Clarke G; Stanton C; Dinan TG; Cryan JF
J Physiol; 2018 Oct; 596(20):4923-4944. PubMed ID: 30066368
[TBL] [Abstract][Full Text] [Related]
9. Alterations in fecal short chain fatty acids (SCFAs) and branched short-chain fatty acids (BCFAs) in men with benign prostatic hyperplasia (BPH) and metabolic syndrome (MetS).
Ratajczak W; Mizerski A; Rył A; Słojewski M; Sipak O; Piasecka M; Laszczyńska M
Aging (Albany NY); 2021 Apr; 13(8):10934-10954. PubMed ID: 33847600
[TBL] [Abstract][Full Text] [Related]
10. Gut-liver axis, nutrition, and non-alcoholic fatty liver disease.
Kirpich IA; Marsano LS; McClain CJ
Clin Biochem; 2015 Sep; 48(13-14):923-30. PubMed ID: 26151226
[TBL] [Abstract][Full Text] [Related]
11. Dietary Polyphenols to Combat Nonalcoholic Fatty Liver Disease via the Gut-Brain-Liver Axis: A Review of Possible Mechanisms.
Wang Z; Zeng M; Wang Z; Qin F; Chen J; He Z
J Agric Food Chem; 2021 Mar; 69(12):3585-3600. PubMed ID: 33729777
[TBL] [Abstract][Full Text] [Related]
12. The role of short-chain fatty acids in kidney injury induced by gut-derived inflammatory response.
Huang W; Zhou L; Guo H; Xu Y; Xu Y
Metabolism; 2017 Mar; 68():20-30. PubMed ID: 28183450
[TBL] [Abstract][Full Text] [Related]
13. G protein-coupled receptors as potential targets for nonalcoholic fatty liver disease treatment.
Yang M; Zhang CY
World J Gastroenterol; 2021 Feb; 27(8):677-691. PubMed ID: 33716447
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic potential of short-chain fatty acid production by gut microbiota in neurodegenerative disorders.
Yadav S; Dwivedi A; Tripathi A; Tripathi AK
Nutr Res; 2022 Oct; 106():72-84. PubMed ID: 36152586
[TBL] [Abstract][Full Text] [Related]
15. Gut microbiome and nonalcoholic fatty liver diseases.
Zhu L; Baker RD; Baker SS
Pediatr Res; 2015 Jan; 77(1-2):245-51. PubMed ID: 25310763
[TBL] [Abstract][Full Text] [Related]
16. Short-chain fatty acids affect the development of inflammatory bowel disease through intestinal barrier, immunology, and microbiota: A promising therapy?
Peng K; Xia S; Xiao S; Yu Q
J Gastroenterol Hepatol; 2022 Sep; 37(9):1710-1718. PubMed ID: 35906780
[TBL] [Abstract][Full Text] [Related]
17. The regulatory roles of dietary fibers on host health via gut microbiota-derived short chain fatty acids.
Xu T; Wu X; Liu J; Sun J; Wang X; Fan G; Meng X; Zhang J; Zhang Y
Curr Opin Pharmacol; 2022 Feb; 62():36-42. PubMed ID: 34896759
[TBL] [Abstract][Full Text] [Related]
18. The Protective Role of Butyrate against Obesity and Obesity-Related Diseases.
Coppola S; Avagliano C; Calignano A; Berni Canani R
Molecules; 2021 Jan; 26(3):. PubMed ID: 33525625
[TBL] [Abstract][Full Text] [Related]
19. The gut-lung axis in severe acute Pancreatitis-associated lung injury: The protection by the gut microbiota through short-chain fatty acids.
Wang Z; Liu J; Li F; Luo Y; Ge P; Zhang Y; Wen H; Yang Q; Ma S; Chen H
Pharmacol Res; 2022 Aug; 182():106321. PubMed ID: 35752356
[TBL] [Abstract][Full Text] [Related]
20. MDG-1, an Ophiopogon polysaccharide, restrains process of non-alcoholic fatty liver disease via modulating the gut-liver axis.
Wang X; Shi L; Wang X; Feng Y; Wang Y
Int J Biol Macromol; 2019 Dec; 141():1013-1021. PubMed ID: 31491513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
